Cargando…
Kinetics of Anti-SARS-CoV-2 Antibody Response Following Two Doses of the BNT162b2 mRNA Vaccine: A Japanese Single-Center Primary Care Clinic Report Involving Volunteers and Patients with Autoimmune Disease
Despite the promising effectiveness of the coronavirus disease 2019 vaccination using an mRNA vaccine, the short efficacy duration and some poor responses to the vaccination remain major concerns. We aimed to clarify the monthly kinetics of the anti-SARS-CoV-2 spike receptor-binding domain antibody...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844396/ https://www.ncbi.nlm.nih.gov/pubmed/36648857 http://dx.doi.org/10.3390/idr15010003 |
_version_ | 1784870646350610432 |
---|---|
author | Sugiura, Tomoko Sugiura, Hiroaki Kato, Hiroaki Nariai, Yuko Mizumoto, Yuuki Hanada, Kozue Takahashi, Rieko Hinotubo, Yukari Tanaka, Naoko Sasaki, Mutsumi Eguchi, Haruki Kamino, Hiroki Urano, Takeshi |
author_facet | Sugiura, Tomoko Sugiura, Hiroaki Kato, Hiroaki Nariai, Yuko Mizumoto, Yuuki Hanada, Kozue Takahashi, Rieko Hinotubo, Yukari Tanaka, Naoko Sasaki, Mutsumi Eguchi, Haruki Kamino, Hiroki Urano, Takeshi |
author_sort | Sugiura, Tomoko |
collection | PubMed |
description | Despite the promising effectiveness of the coronavirus disease 2019 vaccination using an mRNA vaccine, the short efficacy duration and some poor responses to the vaccination remain major concerns. We aimed to clarify the monthly kinetics of the anti-SARS-CoV-2 spike receptor-binding domain antibody response after two doses of the BNT162b2 vaccine in a Japanese population. A chemiluminescent enzyme immunoassay (CLIA) and an enzyme-linked immunosorbent assay were used to measure the antibody levels in 81 Japanese adults (age, <65 years). The antibody levels increased 10-fold at 2–3 weeks following the second dose of BNT162b2 and declined thereafter to approximately 50%, 20%, and 10% of the peak levels at 2, 3, and 6 months, respectively. To compare the antibody titers among different groups, older adults (age, >65 years; n = 38) and patients with systemic lupus erythematosus (SLE, n = 14) were also investigated. A decline in the mean relative antibody titers was observed in older men compared with younger men and in patients with SLE compared with individuals aged <65 years. Although the antibody levels increased drastically following two BNT162b2 doses, they then declined rapidly. Furthermore, poor responders to the vaccination were observed. Repeated vaccinations are required to maintain high antibody levels. |
format | Online Article Text |
id | pubmed-9844396 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98443962023-01-18 Kinetics of Anti-SARS-CoV-2 Antibody Response Following Two Doses of the BNT162b2 mRNA Vaccine: A Japanese Single-Center Primary Care Clinic Report Involving Volunteers and Patients with Autoimmune Disease Sugiura, Tomoko Sugiura, Hiroaki Kato, Hiroaki Nariai, Yuko Mizumoto, Yuuki Hanada, Kozue Takahashi, Rieko Hinotubo, Yukari Tanaka, Naoko Sasaki, Mutsumi Eguchi, Haruki Kamino, Hiroki Urano, Takeshi Infect Dis Rep Article Despite the promising effectiveness of the coronavirus disease 2019 vaccination using an mRNA vaccine, the short efficacy duration and some poor responses to the vaccination remain major concerns. We aimed to clarify the monthly kinetics of the anti-SARS-CoV-2 spike receptor-binding domain antibody response after two doses of the BNT162b2 vaccine in a Japanese population. A chemiluminescent enzyme immunoassay (CLIA) and an enzyme-linked immunosorbent assay were used to measure the antibody levels in 81 Japanese adults (age, <65 years). The antibody levels increased 10-fold at 2–3 weeks following the second dose of BNT162b2 and declined thereafter to approximately 50%, 20%, and 10% of the peak levels at 2, 3, and 6 months, respectively. To compare the antibody titers among different groups, older adults (age, >65 years; n = 38) and patients with systemic lupus erythematosus (SLE, n = 14) were also investigated. A decline in the mean relative antibody titers was observed in older men compared with younger men and in patients with SLE compared with individuals aged <65 years. Although the antibody levels increased drastically following two BNT162b2 doses, they then declined rapidly. Furthermore, poor responders to the vaccination were observed. Repeated vaccinations are required to maintain high antibody levels. MDPI 2022-12-26 /pmc/articles/PMC9844396/ /pubmed/36648857 http://dx.doi.org/10.3390/idr15010003 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sugiura, Tomoko Sugiura, Hiroaki Kato, Hiroaki Nariai, Yuko Mizumoto, Yuuki Hanada, Kozue Takahashi, Rieko Hinotubo, Yukari Tanaka, Naoko Sasaki, Mutsumi Eguchi, Haruki Kamino, Hiroki Urano, Takeshi Kinetics of Anti-SARS-CoV-2 Antibody Response Following Two Doses of the BNT162b2 mRNA Vaccine: A Japanese Single-Center Primary Care Clinic Report Involving Volunteers and Patients with Autoimmune Disease |
title | Kinetics of Anti-SARS-CoV-2 Antibody Response Following Two Doses of the BNT162b2 mRNA Vaccine: A Japanese Single-Center Primary Care Clinic Report Involving Volunteers and Patients with Autoimmune Disease |
title_full | Kinetics of Anti-SARS-CoV-2 Antibody Response Following Two Doses of the BNT162b2 mRNA Vaccine: A Japanese Single-Center Primary Care Clinic Report Involving Volunteers and Patients with Autoimmune Disease |
title_fullStr | Kinetics of Anti-SARS-CoV-2 Antibody Response Following Two Doses of the BNT162b2 mRNA Vaccine: A Japanese Single-Center Primary Care Clinic Report Involving Volunteers and Patients with Autoimmune Disease |
title_full_unstemmed | Kinetics of Anti-SARS-CoV-2 Antibody Response Following Two Doses of the BNT162b2 mRNA Vaccine: A Japanese Single-Center Primary Care Clinic Report Involving Volunteers and Patients with Autoimmune Disease |
title_short | Kinetics of Anti-SARS-CoV-2 Antibody Response Following Two Doses of the BNT162b2 mRNA Vaccine: A Japanese Single-Center Primary Care Clinic Report Involving Volunteers and Patients with Autoimmune Disease |
title_sort | kinetics of anti-sars-cov-2 antibody response following two doses of the bnt162b2 mrna vaccine: a japanese single-center primary care clinic report involving volunteers and patients with autoimmune disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844396/ https://www.ncbi.nlm.nih.gov/pubmed/36648857 http://dx.doi.org/10.3390/idr15010003 |
work_keys_str_mv | AT sugiuratomoko kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease AT sugiurahiroaki kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease AT katohiroaki kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease AT nariaiyuko kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease AT mizumotoyuuki kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease AT hanadakozue kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease AT takahashirieko kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease AT hinotuboyukari kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease AT tanakanaoko kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease AT sasakimutsumi kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease AT eguchiharuki kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease AT kaminohiroki kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease AT uranotakeshi kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease |